Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

Exclusion Criteria

• •Subject receiving any live (includes attenuated) vaccination or immunoglobulins within 56 days preceding the CZP injection.
• •Subject has taken any drugs (including over-the-counter medications) within 56 days preceding the CZP injection (with the exception of those noted in Section 7.8.1.).
• •Subject is known to be intolerant to pegol.
• •Subject has previously received CZP.
• •Subject has received TNFα-inhibitors within 12 months or other biologic within 6 months before randomization into the study.
• •Subject has an active or chronic/latent infection including TB, hepatitis C virus (HCV), hepatitis B core antigen (HBc), or human immunodeficiency virus (HIV).-- Subject has symptomatic herpes zoster infection (shingles) within 6 months prior to Screening.
• •Subject has chronic, serious, opportunistic recurring infection or condition within 6 months prior to Screening.